Patents by Inventor Natalia Alenina

Natalia Alenina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
    Patent number: 11337909
    Abstract: A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: May 24, 2022
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Michael Bader, Fatimunnisa Qadri, Mihail Todiras, Natalia Alenina
  • METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION
    Publication number: 20200360258
    Abstract: A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.
    Type: Application
    Filed: November 29, 2018
    Publication date: November 19, 2020
    Inventors: Michael Bader, Fatimunnisa Qadri, Mihail Todiras, Natalia Alenina
  • Method for modulating, treating and/or preventing metabolic syndrome using MAS-G-protein-coupled receptor agonists
    Patent number: 8586054
    Abstract: The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the manifestations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: November 19, 2013
    Assignees: Max-Delbruck-Centrum fur Molekulare Medizin, Universidade Federal de Minas Gerais
    Inventors: Robson Augusto Souza Dos Santos, Sergio Henrique Sousa Santos, Jaqueline Isaura Alvarez Leite, Marina Matos De Moura, Andrea Siqueira Haibara, Luciana Rodriques Fernandez, Michael Bader, Natalia Alenina, Rubens Dario Sinisterra
  • Use of Mas-G-Protein-Coupled Receptor Agonists in the Treatment of the Metabolic Syndrome, Its Components and its Complications
    Publication number: 20090221498
    Abstract: The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the manifestations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations.
    Type: Application
    Filed: April 26, 2007
    Publication date: September 3, 2009
    Inventors: Robson Augusto Souza Dos Santos, Sergio Henrique Sousa Santos, Jaqueline Isaura Alvarez Leite, Marina Matos De Moura, Andrea Siqueira Haibara, Luciana Rodriques Fernandez, Michael Bader, Natalia Alenina, Rubens Dario Sinisterra